These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21666727)

  • 1. Perspective: recognizing resistance.
    Sylvestre D
    Nature; 2011 Jun; 474(7350):S11. PubMed ID: 21666727
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
    Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
    J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A
    Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of new hepatitis C treatments in different regions of the world.
    Wei L; Lok AS
    Gastroenterology; 2014 May; 146(5):1145-50.e1-4. PubMed ID: 24662488
    [No Abstract]   [Full Text] [Related]  

  • 7. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of interferon resistance in hepatitis C.
    Gretch D
    Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
    [No Abstract]   [Full Text] [Related]  

  • 10. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors.
    Colson P; Purgus R; Borentain P; Gérolami R
    J Clin Virol; 2012 Feb; 53(2):178-80. PubMed ID: 22079973
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical relevance of HCV antiviral drug resistance.
    Welsch C; Zeuzem S
    Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
    Molino S; Martin MT
    Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging antiviral drugs for hepatitis C virus.
    Enomoto M; Tamori A; Kawada N
    Rev Recent Clin Trials; 2009 Sep; 4(3):179-84. PubMed ID: 20028330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance.
    Götte M
    Curr Opin Virol; 2012 Oct; 2(5):644-50. PubMed ID: 22964133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.
    Morsica G; Bagaglio S; Uberti-Foppa C; Galli L; Lazzarin A
    J Acquir Immune Defic Syndr; 2009 May; 51(1):106-8. PubMed ID: 19390331
    [No Abstract]   [Full Text] [Related]  

  • 16. Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.
    Ke R; Loverdo C; Qi H; Sun R; Lloyd-Smith JO
    PLoS Comput Biol; 2015 Jun; 11(6):e1004040. PubMed ID: 26125950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.
    Kim AY; Timm J; Nolan BE; Reyor LL; Kane K; Berical AC; Zachary KC; Lauer GM; Kuntzen T; Allen TM
    J Infect Dis; 2009 Mar; 199(5):737-41. PubMed ID: 19199553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hepatitis C infection in injection drug users in Hong Kong.
    Lee SS
    Hong Kong Med J; 2009 Dec; 15 Suppl 8():45-6. PubMed ID: 20393214
    [No Abstract]   [Full Text] [Related]  

  • 19. Prisons, prisoners, and hepatitis C.
    Ferguson L; Batey R
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1184-6. PubMed ID: 20594243
    [No Abstract]   [Full Text] [Related]  

  • 20. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.
    El Sherif O; Afhdal N; Curry M
    J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.